Novel, fast-acting therapy benefits patients with platelet disorder in phase 2 trial

Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that the investigational medication mezagitamab can effectively boost platelet counts in patients with immune thrombocytopenia (ITP), an autoimmune disease characterized by elevated platelet destruction and reduced platelet production that increases bleeding risk and compromises quality of life.

New yellow fever vaccine matches safety and effectiveness of current shot

Yellow fever is a viral disease that is spread to humans through the bites of infected mosquitoes. The symptoms range from mild fever-like aches and pains to severe liver disease with bleeding, often accompanied by yellowing skin and eyes. As of now, we do not have antiviral drugs to cure these diseases, as most of the treatments are limited to easing symptoms. Hence, prevention via vaccination is our best bet against this disease. A recent study has found that a new yellow fever vaccine, called vYF by Sanofi, works just as well as the current licensed vaccine, YF-VAX.

EV-RNAs show promise for IBD diagnosis and treatment

A research team led by Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, has published a comprehensive review in ExRNA that sorts out the diverse roles of extracellular vesicle-associated RNAs (EV-RNAs) in the development and progression of inflammatory bowel disease (IBD).